WO2025046298 - ANTI-TREM2 ANTIBODIES AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2025/046298
Publication Date
06.03.2025
International Application No.
PCT/IB2024/000473
International Filing Date
30.08.2024
Title **
[English]
ANTI-TREM2 ANTIBODIES AND METHODS OF USE
[French]
ANTICORPS ANTI-TREM2 ET PROCÉDÉS D'UTILISATION
Applicants **
ITEOS BELGIUM SA
Inventors
HOOFD, Catherine
JANSS, Thibaut
PIRSON, Romain
RABOLLI, Virginie
MCGRATH, Yvonne
MARILLIER, Reece
DUBRAY, Quentin
HOYOS, Clotilde
CHESNÉ, Julie
MARTINOLI, Chiara
LOVERIX, Stefan
SAERENS, Laura
Priority Data
63/580,184
01.09.2023
US
63/640,439
30.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7608 | |
| EPO | Filing, Examination, Granting | 186430 | |
| Japan | Filing, Examination, Granting | 5243 | |
| South Korea | Filing, Examination, Granting | 11340 | |
| USA | Filing, Examination, Granting | 36490 |
Total:
247,111
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are anti-TREM2 antibodies. Polynucleotides, vectors, host cells, and methods of production are also provided herein. Methods of treating a disease or disorder, such as cancer with an anti-TREM2 antibody are further provided.[French]
L'invention concerne des anticorps anti-TREM2. L'invention concerne également des polynucléotides, des vecteurs, des cellules hôtes et des procédés de production. L'invention concerne en outre des méthodes de traitement d'une maladie ou d'un trouble, tel qu'un cancer avec un anticorps anti-TREM2.